Business Wire

Octave Presents Data from 13 Abstracts at ECTRIMS Forum 2022 Following Commercial Launch of Precision Care Solution for Multiple Sclerosis

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, a leading digital health sciences company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today ...
Nasdaq

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management

MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, ...
Business Wire

Octave Bioscience’s MSDA Test Proven to Provide Clinically Actionable Insights That Drive Meaningful Clinical Decisions in MS Care

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases ...
MarketWatch

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave(R) Multiple Sclerosis Disease Activity (MSDA) Test Across the ...

The MarketWatch News Department was not involved in the creation of this content. Collaboration enables patients to access the Octave MSDA test at Quest's approximately 7,000 patient access sites ...
Seeking Alpha

Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the ...

Collaboration enables patients to access the Octave MSDA test at Quest’s approximately 7,000 patient access sites across the U.S. and establishes a pathway to introduce additional tests from Octave’s ...